Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"
Manager TitleAgeSince
Corporate Secretary 60 08/08/2019
Director TitleAgeSince
Director/Board Member 60 07/06/2019
Director/Board Member 49 21/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-2.86%-0.26%+57.57%+110.98% 56.42B
-0.34%+2.91%+45.55%+46.87% 44.54B
+1.20%+7.30%-13.72%-18.81% 22.9B
+0.98%+4.81%-2.84%+393.25% 21.21B
-0.51%-5.56%+10.43%-29.97% 16.4B
-1.54%-1.06%+8.10%-39.28% 15.4B
-0.78%+2.10%+26.53%+176.57% 13.35B
+0.96%+6.56%+20.81% - 12.36B
+0.32%+1.60%+96.37%+207.56% 11.15B
Average -0.25%+1.66%+27.64%+105.90% 23.75B
Weighted average by Cap. -0.72%+2.54%+32.21%+98.50%
Logo Nightstar Therapeutics PLC
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company's lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company's third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.
Employees
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!